
In this online, self-learning activity:
Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may lead to permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Both globally and in the U.S., the prevalence of PsA is 0.1% to 1%, but it is a common comorbidity of patients with psoriasis, affecting between a quarter and a half of those with moderate-to-severe disease. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible. In all, patients with PsA incur about four times the direct medical costs as compared to the average medical patient. Yet despite the considerable health and economic burden represented by the disease, delayed diagnosis and misdiagnosis are not uncommon.
HCPs including: rheumatologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in rheumatology and immunology; and any other HCPs with an interest in or who clinically encounter patients with PsA.
Commercial Support Disclosure: This program is supported by an educational grant from UCB.
This activity is free of charge.
Release Date: June 22, 2024 -- Expiration Date: June 22, 2026
Faculty: Vivien Hsu, MD
|
Faculty introduction, disclosures |
|
Introduction content: review of Psoriatic arthritis (PsA)
|
|
Treatment of PsA
|
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202792470
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Vivien M. Hsu, MD, Professor of Medicine, Rutgers - RWJ Medical School, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from UCB.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Spotlight on actinic keratosis: updates in practice and treatment optimization
Recognition and management of epidermolysis bullosa: what the clinician needs to know
Advanced systemic mastocytosis: from recognition to treatment
How implicit bias and culture competence shape the patient healthcare experience